Your browser doesn't support javascript.
A Prospective Study Regarding the Efficacy and Safety of the BNT162b2 Vaccine in Patients With Solid Malignancies Undergoing Systemic Chemotherapy.
Yamasaki, Eiki; Shimamoto, Fukutaro; Nishikawa, Hiroki; Goto, Masahiro; Iwamoto, Mitsuhiko; Kimura, Kosei; Ukimura, Akira; Oosaka, Naofumi; Taniguchi, Kohei; Ono, Fumihito; Terazawa, Tetsuji; Yamaguchi, Toshifumi; Asaishi, Ken; Ikegami, Takako; Uchiyama, Kazuhisa; Nakamura, Shiro; Higuchi, Kazuhide.
  • Yamasaki E; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Shimamoto F; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Nishikawa H; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; nishikawa_6392_0207@yahoo.co.jp.
  • Goto M; Premier Departmental Research of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Iwamoto M; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Kimura K; Department of Breast Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Ukimura A; Department of Breast Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Oosaka N; Third Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Taniguchi K; Department of Central Clinical Laboratory, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Ono F; Translational Research Program, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Terazawa T; Translational Research Program, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Yamaguchi T; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Asaishi K; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Ikegami T; Cancer Chemotherapy Center, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Uchiyama K; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
  • Nakamura S; Dean, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Higuchi K; Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
In Vivo ; 36(6): 2780-2789, 2022.
Article in English | MEDLINE | ID: covidwho-2100679
ABSTRACT
BACKGROUND/

AIM:

To prospectively evaluate the efficacy and safety of the BNT162b2 vaccine in solid cancer patients undergoing systemic chemotherapy (n=63). PATIENTS AND

METHODS:

COVID-19 anti-spike protein antibody levels were measured before the first BNT162b2 vaccination, just before the second BNT162b2 vaccination, one month after the second BNT162b2 vaccination, and 3 months after the second BNT162b2 vaccination. Anti-spike protein antibody seropositivity was set at ≥0.8 U/ml.

RESULTS:

Colorectal cancer was the most commonly observed primary disease (36.5%). ECOG-PS 0 was observed in the majority (52.4%) of patients. The overall response rate and the median (range) anti-spike protein antibody levels in the whole cohort at 3 months after the second BNT162b2 vaccination were 98.4% (62/63) and 206 (0.4-3,813) U/ml. None of the patients required postponement or discontinuation of systemic chemotherapy because of an adverse reaction.

CONCLUSION:

The BNT162b vaccine in solid cancer patients undergoing systemic chemotherapy is effective and safe.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: In Vivo Journal subject: Neoplasms Year: 2022 Document Type: Article Affiliation country: Invivo.13015

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 / Neoplasms Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: In Vivo Journal subject: Neoplasms Year: 2022 Document Type: Article Affiliation country: Invivo.13015